The tumour-associated antigen (TAA) GA733-2 is expressed as a non-secreted surface molecule on the majority of human colorectal carcinoma cells. The antigen has been used as a target for passive and active immunotherapy during the last decade. To determine the incidence of autoantibodies against this antigen, sera from 1068 patients with colorectal carcinoma were analysed for naturally occurring IgG antibodies against the baculovirus-produced GA733-2E protein. A total of 14.5% of the patients had IgG antibodies against the antigen. In 519 patients, sera were collected at the time of diagnosis and 15% of those patients had anti-GA733-2E IgG antibodies. There was a tendency to a higher frequency of patients with antibodies among those in the advanced Dukes stages: 11% in stage A and 32% in stage D respectively (P = 0.06). Antibodies could be detected for up to 10 years after the diagnosis. Patients with Crohn's disease or colitis ulcerosa (n = 20) did not elicit anti-GA733-2E antibodies. No healthy control donor (n = 45) had detectable antibodies against the antigen. The specificity of GA733-2E-reactive serum IgG was indicated by significant inhibition of mAb17-1A (originally used to define GA733-2) binding to the GA733-2E antigen. Sera of positive patients bound to the GA733-2-expressing human colorectal carcinoma cell line, SW948. No significant correlation was found between the presence of antibodies and survival in the present patient population. However, the high incidence of autoantibodies against this tumour antigen in colorectal carcinoma patients confirms its antigenicity in humans and supports the use of the GA733-2 antigen as a target for immunotherapy.
This is a preview of subscription content, log in via an institution to check access.
Access this article Subscribe and saveSpringer+ Basic
€34.99 /Month
Price includes VAT (Germany)
Instant access to the full article PDF.
Similar content being viewed by others Explore related subjectsDiscover the latest articles and news from researchers in related subjects, suggested using machine learning. Author information Authors and AffiliationsImmune and Gene Therapy Laboratory, Department of Oncology (Radiumhemmet), Karolinska Hospital, S-171 76 Stockholm, Sweden Tel.: +46-8-517 75508; Fax: +46-8-31 15 85, , , , , , SE
Szilvia Mosolits, Ulrika Harmenberg, Bo Nilsson & Jan Fagerberg
Swedish Institute for Infectious Disease Control, Stockholm, Sweden, , , , , , SE
Ulla Rudén
Karo Bio AB, Novum, Huddinge, Sweden, , , , , , SE
Lars Öhman
Microbiology and Tumorbiology Center, Karolinska Institute, Stockholm, Sweden, , , , , , SE
Britta Wahren
Department of Experimental Oncology, Uppsala University, Uppsala, Sweden, , , , , , SE
Håkan Mellstedt
Received: 25 May 1998 / Accepted: 26 November 1998
About this article Cite this articleMosolits, S., Harmenberg, U., Rudén, U. et al. Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma. Cancer Immunol Immunother 47, 315–320 (1999). https://doi.org/10.1007/s002620050536
Issue Date: March 1999
DOI: https://doi.org/10.1007/s002620050536
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.4